利拉鲁肽是一种用于治疗2型糖尿病的抗糖尿病药物,肥胖,和慢性体重管理。它是一种胰高血糖素样肽-1(GLP-1)激动剂,可在给药后24小时内帮助减少餐后高血糖。它根据葡萄糖水平刺激内源性胰岛素分泌,并延迟胃排空和抑制餐时胰高血糖素分泌。与利拉鲁肽相关的一些常见并发症包括低血糖,头痛,腹泻,恶心,和呕吐。不常见的不良反应包括胰腺炎,肾衰竭,胰腺癌,和注射部位反应。在这篇文章中,我们讨论了一例73岁的男性,有不受控制的2型糖尿病病史,长期使用胰岛素和利拉鲁肽,表现为腹痛,主观发烧,干燥的天空,心动过速,轻度降低血氧饱和度.根据实验室和影像学检查结果,患者被诊断为胰腺炎。利拉鲁肽被停用,患者接受了支持性治疗,临床明显改善。GLP-1抑制剂的使用不仅在糖尿病管理中增加,而且还因为它对体重管理的积极作用。文献综述支持我们的病例报告发现,并讨论了利拉鲁肽的其他并发症。因此,我们建议在开始使用利拉鲁肽时认识到这些副作用。
Liraglutide is an anti-diabetic medication used for the treatment of type 2 diabetes mellitus, obesity, and chronic weight management. It is a glucagon-like peptide-1 (GLP-1) agonist that helps reduce postprandial hyperglycemia for up to 24 h after administration. It stimulates endogenous insulin secretion according to glucose levels, and also delays gastric emptying and suppresses prandial glucagon secretion. Some of the common complications associated with liraglutide include hypoglycemia, headache, diarrhea, nausea, and vomiting. Uncommon adverse effects include pancreatitis, kidney failure, pancreatic cancer, and injection site reactions. In this article, we discussed a
case of a 73-year-old male with a history of uncontrolled type 2 diabetes mellitus on long-term insulin and liraglutide who presented with abdominal pain, subjective fevers, dry heaves, tachycardia, and mildly reduced oxygen saturation. The patient was diagnosed with pancreatitis on the basis of laboratory and imaging findings. Liraglutide was discontinued, and the patient received supportive care with significant clinical improvement. The use of GLP-1 inhibitors has been increasing not only for diabetes mellitus management, but also for its promising effect on weight management. The literature review endorses our
case report findings, and also discusses other complications of liraglutide. Therefore, we recommend to be cognizant of these side-effects upon starting liraglutide.